Reduced Fhit expression in cervical carcinoma: Correlation with tumor progression and poor prognosis

Gynecologic Oncology

Volumn 90, Issue 2, 2003, Pages 331-337

  Huang, Lee Wen ^a   Chao, Shiouh Lirng ^b   Chen, Tong Jong ^a  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cervical neoplasm; FHIT; Immunohistochemistry; Prognosis; Progression

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; POLYCLONAL ANTIBODY; PROTEIN ANTIBODY;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DYING; FEMALE; GENE EXPRESSION; HEALTH STATUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRECANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; VAGINA;

EID: 0043125693     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00318-4     Document Type: Article

References (35)

1. Walboomer J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kurman J.A., Shah K.V., Snijders P.J.F., Peto J., Meijer C.J.L.M., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:1999;12-19.
2. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 338:1998;423-428.
3. Larson A.A., Kern S., Curtiss S., Gordon R., Cavenee W.K., Hampton G.M. High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Res. 57:1997;4082-4090.
4. Allen D.G., White D.J., Hutchins A.M., Scurry J.P., Tabrizi S.N., Garland S.M., Armes J.E. Progressive genetic aberrations detected by comparative genomic hybridization in squamous cell cervical cancer. Br J Cancer. 83:2000;1659-1663.
5. Wistuba I.I., Montellano F.D., Milchgrub S., Virmani A.K., Behrens C., Chen H., Ahmadian M., Nowak J.A., Muller C., Minna J.D., Gazdar A.F. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res. 57:1997;3154-3158.
6. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t (3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 84:1996;587-597.
7. Boldog F.L., Waggoner B., Glover T.W., Chumakov I., Le Paslier D., Cohen D., Gemmill R.M., Drabkin H.A. Integrated YAC contig containing the 3p14.2 hereditary renal carcinoma 3;8 translocation breakpoint and the fragile site FRA3B. Genes Chromosomes Cancer. 11:1994;216-221.
8. Barnes L.D., Garrison P.N., Siprashvili Z., Guranowski A., Robinson A.K., Ingram S.W., Croce C.M., Ohta M., Huebner K. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5‴ -P1,P3-triphosphate hydrolase. Biochemistry. 35:1996;11529-11535.
9. Siprashvili Z., Sozzi G., Barnes L.D., McCue P., Robinson A.K., Eryomin V., Sard L., Tagliabue E., Greco A., Fusetti L., Schwartz G., Pierotti M.A., Croce C.M., Huebner K. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA. 94:1997;13771-13776.
10. Dumon K.R., Ishii H., Vecchione A., Trapasso F., Baldassarre G., Chakrani F., Druck T., Rosato E.F., Williams N.N., Baffa R., During M.J., Huebner K., Croce C.M. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res. 61:2001;4827-4836.
11. Sozzi G., Pastorino U., Moiraghi L., Tagliabue E., Pezzella F., Ghirelli C., Tornielli S., Sard L., Huebner K., Pierotti M.A., Croce C.M., Pilotti S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 58:1998;5032-5037.
12. Campiglio M., Pekarsky Y., Menard S., Tagliabue E., Pilotti S., Croce C.M. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res. 59:1999;3866-3869.
13. Baffa R., Gomella L.G., Vecchione A., Bassi P., Mimori K., Sedor J., Calviello C.M., Gardiman M., Minimo C., Strup S.E., McCue P.A., Kovatich A.J., Pagano F., Huebner K., Croce C.M. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol. 156:2000;419-424.
14. Mori M., Mimori K., Shiraishi T., Alder H., Inoue H., Tanaka Y., Sugimachi K., Huebner K., Croce C.M. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res. 60:2000;1177-1182.
15. Hao X.P., Willis J.E., Pretlow T.G., Rao J.S., MacLennan G.T., Talbot I.C., Pretlow T.P. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res. 60:2000;18-21.
16. Yoshino K., Enomoto T., Nakamura T., Nakashima R., Wada H., Saitoh J., Noda K., Murata Y. Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix. Int J Cancer. 76:1998;176-181.
17. Yoshino K., Enomoto T., Nakamura T., Sun H., Ozaki K., Nakashima R., Wada H., Saitoh J., Watanabe Y., Noda K., Murata Y. FHIT alterations in cancerous and non-cancerous cervical epithelium. Int J Cancer. 85:2000;6-13.
18. Wilke C.M., Hall B.K., Hoge A., Paradee W., Smith D.I., Glover T.W. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site direct evidence for the coincidence of viral integration sites and fragile sites . Hum Mol Genet. 5:1996;187-195.
19. Birrer M.J., Hendricks D., Farley J., Sundborg M.J., Bonome T., Walts M.J., Geradts J. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res. 59:1999;5270-5274.
20. Nakagawa S., Yoshikawa H., Kimura M., Kawana K., Matsumoto K., Onda T., Kino N., Yamada M., Yasugi T., Taketani Y. A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. Br J Cancer. 79:1999;589-594.
21. Capuzzi D., Santoro E., Hauck W.W., Kovatich A.J., Rosato F.E., Baffa R., Huebner K., McCue P.A. Fhit expression in gastric adenocarcinoma correlation with disease stage and survival . Cancer. 88:2000;24-34.
22. Krivak T.C., McBroom J.W., Seidman J., Venzon D., Crothers B., MacKoul P.J., Rose G.S., Carlson J.W., Birrer M.J. Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma a poor prognostic factor . Cancer Res. 61:2001;4382-4385.
23. Lee J.I., Soria J.C., Hassan K., Liu D., Tang X., El-Naggar A., Hong W.K., Mao L. Loss of Fhit expression is a predictor of poor outcome in tongue cancer. Cancer Res. 61:2001;837-841.
24. Huang L.W., Garrett A.P., Bell D.A., Welch W.R., Berkowitz R.S., Mok S.C. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol. 77:2000;369-376.
25. Greenspan D.L., Connolly D.C., Wu R., Lei R.Y., Vogelstein J.T., Kim Y.T., Mok J.E., Munoz N., Bosch F.X., Shah K., Cho K.R. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res. 57:1997;4692-4698.
26. Sozzi G., Tornielli S., Tagliabue E., Sard L., Pezzella F., Pastorino U., Minoletti F., Pilotti S., Ratcliffe C., Veronese M.L., Goldstraw P., Huebner K., Croce C.M., Pierotti M.A. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res. 57:1997;5207-5212.
27. Druck T., Hadaczek P., Fu T.B., Ohta M., Siprashvili Z., Baffa R., Negrini M., Kastury K., Veronese M.L., Rosen D., Rothstein J., McCue P., Cotticelli M.G., Inoue H., Croce C.M., Huebner K. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res. 57:1997;504-512.
28. Tanaka H., Shimada Y., Harada H., Shinoda M., Hatooka S., Imamura M., Ishizaki K. Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res. 58:1998;3429-3434.
29. Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, Jones RW, Bosch FX, Munoz N, Cho KR. Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 2000: 3505-10.
30. Hadaczek P., Siprashvili Z., Markiewski M., Domagala W., Druck T., McCue P.A., Pekarsky Y., Ohta M., Huebner K., Lubinski J. Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res. 58:1998;2946-2951.
31. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Mereno V., Kurman R., Shah K.V. Prevalence of human papillomavirus in cervical cancer a worldwide perspective . J Natl Cancer Inst. 87:1995;796-802.
32. Schiffman M.H., Bauer H.M., Hoover R.N., Glass A.G., Gadell D.M., Rush B.B., Scott D.R., Sherman M.E., Kurman R.J., Wacholder S., Stanton C.K., Manos M.M. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 85:1993;958-964.
33. Muller C.Y., O'Boyle J.D., Fong K.M., Wistuba I.I., Biesterveld E., Ahmadian M., Miller D.S., Gazdar A.F., Minna J.D. Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer association with human papillomavirus type . J Natl Cancer Inst. 90:1998;433-439.
34. Butler D., Collins C., Mabruk M., Barry Walsh C., Leader M.B., Kay E.W. Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features. J Pathol. 192:2000;502-510.
35. Tomizawa Y., Nakajima T., Kohno T., Saito R., Yamaguchi N., Yokota J. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res. 58:1998;5478-5483.